intermediates, and herbicides accounted for 86% of the hits. Further, changes in MFR occurred in the absence of cytotoxicity, as only eight compounds decreased cell viability. ToxPrint chemotype analysis identified several structural domains (e.g., biphenyls and alkyl phenols) significantly enriched with MEA actives relative to the total test set. The top 5 enriched ToxPrint chemotypes were represented in 26% of the MEA hits, whereas the top 11 ToxPrints were represented in 34% of MEA hits. These results demonstrate that large-scale functional screening using neural networks on MEAs can fill a critical gap in assessment of neurotoxicity potential in ToxCast assay results. Further, a data-mining approach identified ToxPrint chemotypes enriched in the MEA-hit subset, which define initial structure-activity relationship inferences, establish potential mechanistic associations to other ToxCast assay endpoints, and provide working hypotheses for future studies.
Introduction
The US Environmental Protection Agency's (EPA) ToxCast program currently includes over 800 assays covering a wide range of cellular responses and mapped to ~300 signaling pathways (https://www.epa.gov/chemical-research/toxicityforecaster-toxcasttm-data). Whereas the number of assays within ToxCast is large, very few assays focus on endpoints specific to the nervous system and its development (Radio et al. 2015) . In addition, adverse outcome pathways (AOPs; Ankley et al. 2010; Watanabe et al. 2011 ) specifically related to neurotoxicity currently are limited, representing an important knowledge gap (Bal-Price et al. 2015) . The ToxCast Abstract Methods are needed for rapid screening of environmental compounds for neurotoxicity, particularly ones that assess function. To demonstrate the utility of microelectrode array (MEA)-based approaches as a rapid neurotoxicity screening tool, 1055 chemicals from EPA's phase II ToxCast library were evaluated for effects on neural function and cell health. Primary cortical networks were grown on multi-well microelectrode array (mwMEA) plates. On day in vitro 13, baseline activity (40 min) was recorded prior to exposure to each compound (40 µM). Changes in spontaneous network activity [mean firing rate (MFR)] and cell viability (lactate dehydrogenase and CellTiter Blue) were assessed within the same well following compound exposure. Following exposure, 326 compounds altered (increased or decreased) normalized MFR beyond hit thresholds based on 2× the median absolute deviation of DMSO-treated wells. Pharmaceuticals, pesticides, fungicides, chemical chemical library currently undergoing screening includes over 3800 unique compounds, of which the most complete assay coverage, to date, is available for ~1100 compounds tested in the earliest phases of the program. Chemicals tested through phase II of the ToxCast program included ~300 chemicals, mostly pesticides, which were screened previously in phase I, and a larger, more structurally diverse set of ~770 unique chemicals that were chosen to represent the broader environmental exposure and toxicity chemical space (Richard et al. 2016) . Compound categories represented within this ~1100 chemical portion of the phase II test set examined in the present study include pesticides, pharmaceuticals, antimicrobials, flame retardants, foodadditives, and "green" chemicals, among others. Several of these compound categories, specifically those classified as insecticides, are known to disrupt the function of ion channels, leading to neurotoxicity (Coats 1990; Narahashi 2002; Tomizawa and Casida 2005) . Within the AOP framework, disruption of ion channel function and changes in cellular excitability may serve as AOP molecular initiating events (MIEs) and key events (KEs), leading to neurotoxicity following compound exposure.
Measuring changes in firing rates and patterns of extracellularly recorded action potentials from neural networks grown in vitro on microelectrode arrays (MEAs) can be an efficient and accurate approach to screen compounds for neurotoxicity hazard (for review, see Johnstone et al. 2010) . Primary cortical cultures grown on multi-well MEAs (mwMEAs) exhibit spontaneous electrical spikes and groups of spikes (bursts) that are associated with neuronal action potentials (Nam and Wheeler 2011) and are sensitive to modulation by glutamatergic agonists and antagonists (Martinoia et al. 2005; Xiang et al. 2007; Frega et al. 2012; Lantz et al. 2014; Hondebrink et al. 2016 ). This technique is reproducible across laboratories Vassallo et al. 2017 ) and sensitive to a broad range of drugs (Colombi et al. 2013; Hondebrink et al. 2016) , toxins (Pancrazio et al. 2014; Nicolas et al. 2014; Alloisio et al. 2016) and chemicals (van Vliet et al. 2007; Alloisio et al. 2015; Duarte et al. 2017) . The procedure measures function rather than a specific biochemical or morphological endpoint, making it a viable option to assess compound effects on neural activity (for review, see Johnstone et al. 2010) . The rates and patterns of activity measured by mwMEAs are sensitive to disruption through a variety of pathways Valdivia et al. 2014) and compound effects are concentration-dependent (Frega et al. 2012; Mack et al. 2014; Nicolas et al. 2014; Hondebrink et al. 2016) .
The development of mwMEA platforms has increased throughput while maintaining high specificity and sensitivity, thereby making this technology ideal for the screening of compound sets to determine functional changes in neural networks (Valdivia et al. 2014; Nicolas et al. 2014; Hondebrink et al. 2016; Newberry et al. 2016; Duarte et al. 2017) . Furthermore, the advent of higher-throughput MEA systems has allowed for the development of a multiplexed approach that permits in-well determination of compound effects on both neurophysiology and cellular viability (Wallace et al. 2015) . Thus, this multiplexed approach provides assessment of both effects on neural network function and cell health within the same network, ensuring the ability to differentiate between compound-induced changes in neural activity and overall reductions in cell health in response to treatment with compounds. Recent studies using small (20-100) compound sets McConnell et al. 2012; Valdivia et al. 2014; Nicolas et al. 2014 ) have demonstrated that changes in spontaneous neural network activity using mwMEAs can identify compounds that are neuroactive and/or neurotoxic with high sensitivity and specificity. However, this approach has not been applied to larger (>100) compound sets.
The present studies were designed to demonstrate the utility of mwMEAs for screening large chemical sets for effects on neural networks. A single concentration screen (40 µM) of compounds in EPA's ToxCast phase II library (~1100 chemicals) was conducted in primary cultures of cortical neural networks. In addition to determining compound effects on spontaneous neural firing rates, cell health was determined in-well by assessing lactate dehydrogenase (LDH) release and effects on mitochondrial activity using CellTiter Blue (CTB). This approach addresses an important data gap for neuroactivity of compounds in the ToxCast chemical space. In addition, the present study conducted initial analyses that provide a basis for utilization of the data for a variety of purposes, including AOP development, prioritization of additional chemical sets, structure-activity relationships and read-across screening.
Materials and methods

Chemical selection and preparation
The ToxCast chemical set provided for the current study consisted of a total of 1101 plated samples, which included 1055 unique chemical substances. This set of chemicals comprised the major portion of chemicals submitted for the full battery of testing in phase II of the ToxCast program, and included the re-procured set of 293 unique compounds tested in phase I (denoted ph1_v2), and a newly added set of 768 compounds (denoted ph2). Nine ph1_v2 compounds served as plating replicates along with 2 copies of 5α-dihydrotestosterone, for a total of 56 samples included for internal quality control. Bicuculline (BIC) methiodide was subsequently added to test plates to serve as a positive MEA control; thus a total of 1056 compounds were screened. A complete current listing of compounds represented in the ToxCast chemical library, including annotation of the phase II chemical inventory subsets screened in the present study, i.e., ph1_v2 and ph2, is available for download at ftp://epa. gov/dsstoxftp and is described in Richard et al. (2016) .
Stock solutions of each compound used in the present study (made to a target concentration of 20 mM in dimethyl sulfoxide, DMSO) were received from EPA's ToxCast Chemical Contractor (Evotec, South San Francisco, CA, USA) in 50 µL aliquots in sealed, round-bottom 96-well plates. Upon arrival, 96-well plates were wrapped in parafilm and stored at −20 °C until use. Prior to each experiment, compounds were thawed and immediately diluted 1:10 in NB/B27 media in a v-bottom 96-well plate for dosing. To dose, 10 µL from the dosing plate was transferred to the designated well on the 48-well mwMEA plate containing primary cortical cultures. Each well of the mwMEA plate contained 500 µL of medium, resulting in a final concentration of 40 µM for each compound. DMSO (0.2% by volume; n = 3 wells/plate), GABA A antagonist bicuculline (25 µM BIC; n = 2 wells/plate), and one well per mwMEA plate was reserved as a lysis control to determine total levels of lactate dehydrogenase (LDH) (see details below). To complete the single-point concentration screen of all compounds from the phase II libraries, ~42 compounds were screened per week in triplicate over ~30 weeks.
Primary cortical culture on mwMEAs
Prior to plating rat primary cortical cultures, mwMEA plates from Axion Biosystems Inc. (Atlanta, GA, USA) were prepared for culture by coating with polyethyleneamine as previously described (Valdivia et al. 2014) . Each 48-well mwMEA plate consisted of a total of 768 nano-textured gold platinum microelectrodes (~40-50 µm diameter, 350 µm center-to-center spacing) with 16 electrodes/well plus four integrated ground electrodes (M768-KAP Kapton, Axion Biosystems Inc., Atlanta, GA, USA).
All procedures involving laboratory animals were approved by the EPA National Health and Environmental Effects Research Laboratory's institutional laboratory animal health care and use committee and were in compliance with applicable federal guidelines for laboratory animal experimentation. Primary cortical neural cultures were prepared as previously described (Mundy and Freudenrich 2000; Valdivia et al. 2014 ) from Long-Evans pups on postnatal day 0-1, with minor modifications. Additional details can be found in the Supplementary Methods. Full media changes occurred on days in vitro (DIV) 5 and 9, while cells received a 1/2 media change on DIV 12 (24 h prior to experiment). The mixed primary culture used for the present experiments consists of glutamatergic and GABAergic neurons and glia (Mundy and Freudenrich 2000) . The neurons possess both axons and dendrites (Harrill et al. 2013) , form synapses , and exhibit spontaneous activity (spikes and bursts) that is blocked by tetrodotoxin (Wallace et al. 2015) and is correlated with neurite length .
Multiplexed screening approach
The present experiments used a multiplexed approach to examine the effects of ToxCast library chemicals on spontaneous neural activity and cell health in primary cortical cultures. Effects on cell health were determined immediately following the conclusion of the electrophysiological recording, in the presence of the compound, using two commercially available assays: LDH and CTB (Wallace et al. 2015) . A more detailed description of the viability assays is found in the Supplementary Methods.
MEA recordings
Spontaneous activity in the cortical cultures was recorded using an Axion Biosystems Maestro 768 channel amplifier and Axion Integrated Studios (AxIS) v1.8 (or later) software. The amplifier recorded from all channels simultaneously (gain = 1200×; sampling rate = 12.5 kHz/channel). Recordings were conducted at 37 °C and filtered with a Butterworth band-pass filter (300-5000 Hz), which removes slower local field potentials, leaving only fast potentials "spikes" associated with action potentials (Pine 2006; Nam and Wheeler 2011) . On-line spike detection was performed with the AxIS adaptive spike detector, using a threshold of 8× the root mean square (rms) noise on each channel. Any electrode with rms noise levels greater than 5 µV was grounded (i.e., no data were recorded). Once grounded, an electrode remained grounded for all subsequent treatments. Wells were deemed usable if on the day of the exposure ≥10 electrodes were active (defined as ≥5 spikes/min). On DIV 13, a minimum of three wells on separate plates from one cortical culture preparation were treated with each compound at a single concentration (40 µM; N = 3). Compounds were tested in only one culture unless a known problem was identified (e.g., contamination, missed or twice dosed wells, solubility issues, etc.). This single concentration approach has been widely utilized in other ToxCast assays (Knudsen et al. 2011; Sipes et al. 2013; Karmaus et al. 2016) . Prior to recording baseline activity, each mwMEA plate was placed in the Maestro at 37 °C and allowed to sit for 20 min while firing rates stabilized. Baseline activity (40 min) was recorded before the addition of each compound. An additional 40 min of spontaneous activity was recorded in the presence of each compound. Changes in mean firing rate (MFR) relative to baseline were assessed following compound treatment.
Assay data analysis
To assess compound effects on network firing rates, the MFR in each well was normalized according to the following formula: nMFR = −1(MFR T − MFR B )/(0 -MFR B ), where nMFR is the normalized mean firing rate, and MFR T and MFR B are the mean firing rates after treatment and baseline recordings, respectively. The median and median absolute deviation (MAD) of nMFR for all wells treated with DMSO were determined, and treatments where the median nMFR exceeded twice the MAD of DMSO-treated wells, in either the up or down direction (i.e., increase or decrease), were considered hits (Sipes et al. 2013 ). The MAD value and consequent hit thresholds are provided in Results. A full listing of the 1056 unique chemical substances (1055 ToxCast compounds + bicuculline methiodide) tested in the current study is provided in Supplemental Table S1 , along with the overall nMFR hit assignment (up, down, hit, or no-hit) and with chemical annotations (including SMILES structures) provided by EPA's Distributed Structure-Searchable Toxicity (DSSTox) database (accessible from EPA's Chemistry Dashboard at https://comptox.epa.gov/dashboard).
CPCat category analysis
The Chemical Products Categories (CPCat) database contains assignments of use categories (e.g., pesticides, pharmaceuticals, cosmetics, etc.) and biological target activities (e.g., estrogen and androgen receptor binders, ERS1 and AR) for tens of thousands of chemicals in commerce and the environment (Dionisio et al. 2015) . Compound target and use associations were programmatically compiled by cross-referencing CASRN to hundreds of chemical lists that were, in turn, tagged by association to various uses and aggregated within the EPA's ACToR database (Judson et al. 2009 ). Where data were available to annotate a CASRN record, a single primary use and biological target was assigned to each chemical within CPCat. The DSSTox CASRN list associated with the current mwMEA-tested chemical list was used to query the CPCat database content within the iCSS ToxCast Dashboard (http://actor.epa. gov/dashboard2/, accessed 6/1/2016), and yielded a list of primary biological targets for approximately half of the mwMEA-tested chemicals (539 total), and use categories for all compounds in the original tested chemical list (excluding bicuculline methiodide, which was subsequently assigned to use category "Pharmaceutical").
ToxPrint chemotype analysis
To explore possible chemical substructural feature (i.e., chemotype) enrichments in the MEA active set (i.e., hits) relative to the total tested set, the publicly available ToxPrint feature set (V2.0_r711; https://toxprint.org/) was employed along with the associated Chemotyper visualization application (https://chemotyper.org/), both developed by Altamira (Altamira, Columbus, OH, USA) and Molecular Networks (Molecular Networks, Erlangen, GmbH) under contract from the US Food and Drug Administration (FDA) (Yang et al. 2015) . A chemical structure-data (SD) file for the phase II ToxCast chemicals screened in the current study (i.e., ph1_ v2, ph2) was exported from the DSSTox database, and can be generated from the publicly available DSSTox TOXCST SD file (available from the DSSTox Data download page at ftp://epa.gov/dsstoxftp). The SD file was imported into the public Chemotyper, mapped to the public set of 729 ToxPrints, and exported as a binary [1,0] fingerprint file to support further analysis. Screenshots of search results displayed within the Chemotyper application were used to generate all pictorial representations of the ToxPrints and their superposition onto ToxCast chemicals.
ToxPrint chemotype (CT) enrichment statistics were evaluated in the MEA hit space (i.e., 318 active MEA chemicals with structures) relative to the full set (1028 MEA-tested chemicals with structures). The smaller number of CTs (318 active/1028 MEA-tested) is because not all substances could be assigned structures [for example mixtures, such as C10-21 sulfonic acids phenyl esters (DTXSID1047526) or milbemectin (DTXSID8034742)]; bicuculline methiodide also was not included. Enrichment was based on a computed odds ratio (OR) for each CT according to the following formula:
where Tpos = True Positive (chemical is MEA hit and contains CT), Tneg = True Negative (chemical is not MEA hit and does not contain CT), Fpos = False Positive (chemical is MEA hit and does not contain CT), Fneg, False Negative (chemical is not MEA hit and contains CT). Additionally, the Fischer's exact test (using the R package script, https:// www.r-project.org/) was used to compute the p value significance of the enrichments, which gives greater weight to enrichments within larger CT sets, i.e., containing larger numbers of chemicals. OR values >3 and p value ≤0.05 cutoffs were used to filter the CT results for significance and further examination. Similarly, the OR and p value significance of ToxPrint CT enrichments were previously computed (K. Connors, unpublished results) for the full suite of publicly available ToxCast assay results (the latter available at https://www.epa.gov/chemical-research/toxicity-forecaster-toxcasttm-data). Consulting the precomputed ToxCast assay CT enrichment results (in each assay's hit space) for the same CTs found to be enriched in the mwMEA assay allowed for the identification of a subset of ToxCast assay endpoints that could be potentially mechanistically related to altered neural network function.
(1) OR = Tpos × Tneg ∕ (Fpos × Fneg),
MEA reference set
For the purposes of evaluating concordance of the current mwMEA results to previously published MEA results, and to serve as a literature reference set for future studies, a curated DSSTox structure file was created that consolidated results for chemicals for which MEA results from one or more labs had been reported previously. For the purposes of this exercise, MEA hit calls (Hit, Neg) that were generated by somewhat different experimental protocols as they evolved over time, were collapsed to the DSSTox chemical substance level and consolidated into a single table. DSSTox curation resulted in some MEA results being mapped to slightly different chemical forms (e.g., Muscimol and Muscimol hydrobromide), and merging of some MEA results based on review of reported CASRN and names (e.g., fluoxetine and fluoxetine hydrochloride). The resulting MEA literature reference list (denoted MEA_Ref), consisting of source names and CASRN accurately mapped to DSSTox identifiers for 146 unique substances, and annotated with references and curation notes, is provided in Supplemental Table S2 .
Results
Data were collected for a total of 4218 wells from 90 mwMEA plates across 30 different cortical culture preparations. The average MFR over all the wells during baseline recordings was 113.11 ± 58.5 (mean ± SD) spikes/min with each well having an average of 14.87 ± 2.4 (mean ± SD) active electrodes. The overall change in response to DMSO was a decrease from a baseline of 121 ± 48 to 101 ± 42 (mean ± SD, n = 81 wells) spikes/min; this decrease was similar to that observed by Valdivia et al. (2014) . BIC caused an increase to 125 ± 57% (mean ± SD, n = 54 wells) of baseline values. It should be noted that the values reported here have not been normalized so that they may be compared to previous work (McConnell et al. 2012; Valdivia et al. 2014 ).
Compound effects on mean firing rate
The distribution of the nMFR is presented in Fig. 1 and is clearly skewed towards compounds that decreased nMFR. DMSO, the solvent control, decreased the median nMFR scores by 23.21%. Compound "hit" thresholds were determined using 2× median absolute deviation (MAD) of DMSO-treated wells (MAD = 21.7; hit thresholds were −65 and +20). Overall, 308 compounds decreased nMFR below the lower hit threshold ("hits down") and 18 increased nMFR above the upper hit threshold ("hits up"; Fig. 2, top) . Compounds were deemed cytotoxic if they induced >20% increase in LDH release and/or decreased mitochondrial activity to <80% of control values. This is a slightly more conservative threshold than that used by Karmaus et al. (2016) for determination of the maximally tolerated concentrations (<70% cell viability) of ToxCast compounds in adrenocortical carcinoma cells. By this measure, only 8 compounds (UK-337312, tributyltin chloride, tributyltin methacrylate, phenylmercuric acetate, 9-phenanthrol, gentian violet, mercuric chloride, and ketoconazole) decreased cellular viability following exposure. All 8 compounds decreased CTB signal below its threshold for cytotoxicity, and all but 3 of these (9-phenanthrol, gentian violet and mercuric chloride) increased the LDH signal above its threshold for cytotoxicity. All eight of these compounds decreased nMFR beyond the hit threshold, and thus are considered "hits", but are flagged as cytotoxic. Interestingly, the four metals and gentian violet were identified as five of the seven most promiscuous compounds in other ToxCast assays (Sipes et al. 2013) . , where nMFR is the normalized mean firing rate, and MFR T and MFR B are the mean firing rate after treatment and baseline recordings, respectively. The mean and median absolute deviation (MAD) of nMFR for all wells treated with DMSO was determined, and treatments where the median nMFR exceeded 2× the MAD of DMSO-treated wells were considered hits (noted as "Lower Threshold" and "Upper Threshold" on histogram). Following exposure, a total of 325 compounds altered MFR beyond threshold, with 308 compounds decreasing activity (red) and 17 compounds increasing (green) network activity (color figure online)
Evaluation of assay performance
Assay performance was evaluated using three concordance metrics: comparing replicate results within the current tested compound set; assessing intra-laboratory consistency by comparing the current results with those from Valdivia et al. (2014) for overlapping compounds; and more broadly comparing the current results with the consensus results in the MEA_Ref list for overlapping compounds.
Ten compounds were included as replicates in the present test set, generating a total of 33 test results (Supplemental Table S3 ). With respect to hit calls, 6/10 replicated compounds (clorophene, bisphenol A, oryzalin, triadimenol, triclosan, and allethrin) demonstrated 100% concordance among all 20 sample replicates, with all 6 compounds labeled as "down" hits. For 3 of the 4 remaining compounds (5α-dihydrotestosterone, azoxystrobin, and mancozeb), all 9 replicate nMFR values decreased, but only 4/9 decreased nMFR greater than the hit threshold. Perfluorooctane sulfonate (PFOS) was the most inconsistent of the replicate compounds; 3/4 replicates increased nMFR (two increased greater than the hit threshold), whereas one replicate decreased nMFR slightly. Differences in the responses did not correlate to the lot number of the compounds in any case.
The current set of MEA hits were also compared to the results for the ToxCast compounds previously screened in a single lab by Valdivia et al. (2014) . Despite differences in hit-call methodology (Valdivia et al. 2014 used weighted MFR) , there was 74% overall concordance in hit calls for the 87 compounds common to both data sets (Supplemental Table S2 ). In 8/23 non-concordant hit calls, the overall changes in nMFR and weighted MFR were similar, but hit thresholds (based on DMSO-treated wells in each study) were different.
Extending the comparison of the current mwMEA results to the full overlapping set of 92 compounds in the MEA_Ref dataset of 146 compounds, which combined the results of several published studies from different laboratories, an overall concordance of 71% was computed. Of the 92 compounds in the overlapping set, the MEA_Ref consensus calls classified 76% (70/92) as hits, whereas the present study (mwMEA), identified 60% (55/92) as hits. This implies lower sensitivity but higher specificity of mwMEA results relative to previously published (MEA_Ref) results. Furthermore, the current mwMEA hit calls agreed with 49/70 (i.e., 70%) of the MEA_Ref hits, whereas a significantly larger fraction of the mwMEA hits, 49/55 (i.e., 89%), was confirmed as hits in the MEA_Ref dataset (Supplemental Table S2 ).
Categories enriched with active compounds
The CPCat database was used to determine the category assignment of compounds hits in the present data (Supplemental Table S4 ). Note that the categories used here differ from legal definitions under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), wherein herbicides, fungicides, biocides and insecticides are all sub-categories of "pesticides". Mirroring the overall composition of the full chemical set tested in the mwMEA assay, a large majority, Fig. 2 Compounds designed to be biologically active comprise the majority of hits. A total of 1055 unique compounds from EPA's ToxCast phase 2 libraries were screened at a single concentration (40 µM) in primary cortical cultures grown on mwMEA plates to determine acute (40 min) effects on neural network function. Top a total of 325 compounds altered network firing rates (MFR) beyond threshold with 308 compounds decreasing activity. In addition to decreasing activity, eight of these compounds were also cytotoxic. A total of 18 compounds (including bicuculline methiodide) increased MFR, while 730 compounds did not alter MFR beyond either threshold. Middle of the 326 compound identified as hits in the mwMEA assay, 253 compounds (~78%) were categorized for use in five major categories within ToxCast. These categories were pesticides (56), pharmaceuticals (87), microbiocides/fungicides (67), herbicides (36), and chemical intermediates (33). Bottom a total of 121 compounds (including bicuculline methiodide) out of the 326 total hits could be assigned to gene targets or modes of action (Supplemental Table 4 ). Shown here are any target genes/MOAs that contained five or more compounds, and the total number of compounds assigned to that category. Of the 205 compounds not represented, 87 did not have an assigned target gene/MOA in CPCat 86%, of the hits (Fig. 2, middle) could be assigned to five compound CPCat "use categories", i.e., pharmaceuticals (87), microbicides/fungicides (67), pesticides (56), herbicides (36), and chemical intermediates (33) Furthermore, three of these-pharmaceuticals, microbicides/fungicides, and pesticides-contained a much higher percentage of mwMEA hits than the overall hit rate, 31%, observed in the full test set (Fig. 3) . Other use categories, including Solvents, Plasticizers, Food Flavor Fragrances, Chemical Intermediates and Surfactants, contained a much lower percentage of hits than were observed in the full test set.
Several of the compounds represented in pesticides and herbicides are either known or suspected to target the nervous system. All 56 of the Pesticide compounds were further classified for use as Insecticides. Thus, this use category included a number of compounds known to act on sodium ion channels (e.g., prallethrin, fenpropathrin, cypermethrin, allethrin, methoxychlor, and tetramethrin) or inhibit acetylcholinesterase activity (e.g., aldicarb, pirimicarb, oxamyl, thiodicarb, dimethoate). Compounds known to act on the GABA A receptor (e.g., fipronil, aldrin, and lindane) were also among those represented in this category. Active compounds classified as Herbicides (37 total) included both dinitro analine alkylates (e.g., prodiamine and flumetralin) and carbamates (e.g., chlorpropham, and tri-allate). A total of 67 compounds used as microbicides/fungicides were active. Compounds in this category included strobins (e.g., picoxystrobin, azoxystrobin) and conazoles (e.g., tebuconazole, tetraconazole, fenbuconzaole).
Pharmaceuticals represented the largest use category within both the tested set of chemicals and within the MEA hit set, with a total of 87 compounds altering network function. Compounds represented in this category included steroids (5α-dihydrotestosterone, 17α-estradiol, and mifepristone), as well as compounds known to target calcium (amiodarone hydrochloride) and sodium (MK-274) ion channels and opioid receptors (methadone hydrochloride and enadoline). Compounds acting on serotoninergic (fabesetron hydrochloride, volinanserin, SB243213A, elzasonan, PD 0343701) and dopaminergic (haloperidol and chlorpromazine hydrochloride) processes were also active and altered network activity beyond threshold.
When examining compound targets, a total of 121 compounds altering neural network function beyond the hit thresholds were associated with targets in CPCat (Fig. 2,  bottom) . Some compounds known to act on these identified targets have been shown previously to alter activity in neuronal networks grown on MEAs. The identified targets included acetylcholinesterase (AChE), as well as GABA A receptors (e.g., lindane, abamectin, fipronil), glutamate, and voltage-gated calcium and sodium channels (e.g., allethrin, tetramethrin). By contrast, several additional targets were identified wherein compounds acting on those targets have not been previously demonstrated to alter activity in neural networks on MEAs. These include estrogen receptor 1 (ESR1), microtubule disruptors, mitochondrial disruptors, sterol biosynthesis inhibitors and tachykinin receptor 1 (TACR1, or substance P receptor). The enrichment of hits in specific compound categories (e.g., pesticides/insecticides) and the observation that multiple hits are found within some chemical classes (e.g., pyrethroids, conazoles) warrants a more rigorous analysis of the MEA hit space.
ToxPrint chemotype enrichment analysis
A cheminformatics data-mining approach using the publicly available ToxPrint structure feature set (referred to as chemotypes, or CTs) was used to explore more systematically possible enrichments of well-defined substructures in the MEA hit space. A statistically significant CT-MEA enrichment indicates that a structural feature (CT) occurs more often in the MEA hit space (i.e., MEA active subset) than in the overall tested space (i.e., all MEA tested chemicals). The top 11 ToxPrint CTs, meeting the statistical threshold criteria OR ≥3 and p value ≤0.05 for the 318 MEA hits (up or down) for which DSSTox structures could be assigned relative to the total tested set of 1028 structures, along with sensitivity and specificity metrics for constructing a standard confusion matrix, are provided in Supplemental Table S5 .
These results are presented graphically in Fig. 4 , with the blue bars representing enrichments as percentages exceeding the 30% total hit rate within the full MEA tested structures set (i.e., 318/1028), the orange dots indicating the total number of chemicals in the CT subgroup (CT-Tot), and a sample of four ToxPrint CT images shown. For a full listing of the 1028 MEA-tested chemicals with structures mapped to the Table S6 . To illustrate how ToxPrint CT enrichments can be explored further within a data mining workflow, cases involving the 4 ToxPrint CT graphs in Fig. 4 are considered in more detail below.
Figure 5 displays all chemical structures within the MEA test set containing either CT479 (chain:aromaticAlkane_Ph-C1-Ph) or CT488 (chain:aromaticAlkene_Ph-C2_acyclic_ generic), with MEA hits indicated within separate boxes. The OR enrichment statistics for the CT479 and CT488 groups are 5.4 and 4.3, respectively. An overlapping set of 9 compounds containing both CT479 and CT488 is represented in the center box, with 8/9 hits corresponding to a much higher OR (18.3) than either CT group separately. Interestingly, once this overlap set is removed from the CT488 superset, there is no significant activity enrichment remaining for the CT488 set (OR = 1.9) indicating that the co-occurrence of CT488 with CT479 is necessary for activity. Figure 6 presents a second example illustrating how ToxPrints can be augmented with new rules to a local CT domain. CT482 (chain:aromaticAlkane_Ph-C6) is present in relatively few chemicals, but has a relatively high odds ratio (4/5 hits, OR = 9.0). The related CT481 (chain:aromaticAlkane_Ph-C4) is present in a few more chemicals, but with less significant enrichment (5/7 hits, OR = 3.0). However, augmenting CT481 with a proposed rule stating that chemicals within the group are MEA active only if they contain a p-hydroxyl and inactive otherwise (i.e., CT481_R1) correctly classifies all 7 compounds. Figure 7 shows 6 tested chemicals containing the enriched CT665 (ring:hetero_[6]_N_O_1_4-oxazine_generic), 5 of which are MEA hits (green border). A list of 6 ToxCast assays additionally found to be significantly enriched with hits in the CT665 chemotype subgroup (OR >4) are listed to the right of the figure (see Supplemental Table S7 ). These include three G-protein coupled (opiate) receptor binding assays (NVS_GPCR) and three rat ion channel receptor binding assays (NVS_IC_r…), all targets that are considered mechanistically relevant to MEA activity. Further strengthening the association of the mwMEA assay results to these six ToxCast assays, CT479, representing a distinct chemical domain and a different set of chemicals, was also found to be significantly enriched in the same six ToxCast assays (OR >4). Additionally, four of the five active chemicals within the CT665 subgroup shown in Fig. 7 were found to be hits in one or more of the rat ion channel receptor binding assays, further strengthening possible associations between the mwMEA assay and these ToxCast assay targets. Following a similar line of inquiry to this example, the MEA-enriched CT482 (chain:aromaticAlkane_Ph-C6) from the previous example in Fig. 6 was significantly enriched in 16 endocrine-related ToxCast assays (see Supplemental Table S8 ), most likely due to the known enrichment of phenols in activating estrogenic (ER) and androgenic (AR) targets.
Discussion
The present study examined 1055 unique compounds in EPA's ToxCast phase II library to determine effects on spontaneous neural network activity and cell health in primary cortical cultures. These data provide the most comprehensive examination of compound effects on neural network function available to date and build upon previous studies examining the effects of ToxCast compounds using small cohorts of compounds (~100) suspected or known to be neuroactive (Valdivia et al. 2014) . In the present experiments, 326 compounds (~30%) altered MFR beyond one of two thresholds, with 18 compounds (including the positive control, bicuculline methiodide) increasing MFR and 308 Center box contains 9 chemicals (8 MEA hits, 1 non-hit) that share both CT479 and CT488 chemotypes with a higher enrichment statistic (OR = 18) than either CT479 or CT488 alone. Furthermore, when the CT479_AND_CT488 overlap set is removed from the CT488 set, the remaining chemicals show no significant enrichment of MEA hits (OR = 1.9) (color figure online) Fig. 6 Chemicals containing ToxPrint CT482 (chain:aromaticAlkane_Ph-C6) are nested within the less restricted CT481 (chain:aromaticAlkane_Ph-C4) chemotype set and yield a higher MEA hit odds ratio statistic (OR = 9.0 vs 3.0) due to the larger percentage of MEA hits (green border) vs. MEA non-hits (gray border); however, when a rule (denoted R1) requiring a p-hydroxyl substitution for MEA activity is added to CT481, all 7 chemicals are correctly classified (color figure online) Fig. 7 All six MEA-tested chemicals containing CT665 (ring:hetero_[6]_N_O_1_4-oxazine_generic) are shown on left, five of which are MEA hits (green border). A sample of ToxCast assays found to also be significantly enriched with hits in both the CT665 and CT479 chemotype subgroups (OR >4) are listed, including three G-protein coupled (opiate) receptor binding assays (NVS_GPCR) and three rat ion channel receptor binding assays (NVS_IC_r…), all of which could be potentially relevant to MEA activity. Upon further examination, four of the five MEA hits within the CT665 subgroup shown were found to have one or more activities in the rat ion channel receptor binding assays, strengthening possible associations among the assays (color figure online) compounds decreasing MFR following 40-min exposure at a single concentration (40 µM). While future evaluation of concentration-response relationships for active compounds will provide information on potency and efficacy for comparison across ToxCast Assays, the present results are informative even without this information.
The ToxCast program includes a wide range of cell-based assays covering a number of key signaling pathways. However, few assays are cell-based, functional assays that focus on endpoints specific to the nervous system and its development. The advent of higher-throughput MEA platforms, in addition to the development of multiplexing protocols (Wallace et al. 2015) allowing for the collection of multiple in-well measurements from the same network, have made mwMEA systems a viable tool for efficiently screening large (>1000) sets of compounds. In the present study, 1102 samples (1101 ToxCast + bicuculline) were screened in triplicate in 48-well MEA plates in a timely fashion, even without the benefit of automation for any aspect of the assay workflow; a significant advancement in screening capability which previously relied upon single well recordings.
In the present study, the performance of the assay as assessed by several measures was reliable. Replicate samples within the plating set provided generally consistent results, even if in four cases the resulting hit calls were divergent due to the selection of hit cutoffs. When comparing compound effects in this study to previous studies, the level of concordance is similar to reports from other laboratories, wherein ~70-80% of neuroactive compounds were identified by neural networks on MEAs (Valdivia et al. 2014; Defranchi et al. 2011; McConnell et al. 2012) . Two caveats should be noted with respect to the MEA reference set used for these comparisons. Firstly, it has some bias towards data generated from this laboratory, so in some respects, this analysis may be more representative of within-laboratory reproducibility. Secondly, only ~8 compounds (e.g. bicuculline, carbaryl, fluoxetine, domoic acid, deltamethrin, verapamil, chlorpyrifos oxon and fipronil) have been tested multiple times in multiple laboratories. Thus, without more rigorous testing of larger numbers of compounds by multiple laboratories, it is difficult to have high confidence in the outcome (Hit or Neg) for any given compound. Two studies with very limited numbers of compounds (3-6) have demonstrated high reproducibility between multiple (4-6) laboratories Vassallo et al. 2017 ). Improvements in screening methods (i.e., collecting triplicate measurements on the same date) for large compound sets have reduced variability associated with handling of mwMEA plates and freeze/ thaw of compounds (Malo et al. 2006; Wallace et al. 2015) . However, additional improvements, including automated plating of cultures and automated dosing, could be used to increase further throughput for large compound sets, while decreasing variability and errors associated with the assay.
For example, it could be that the most discordant of the four replicates of PFOS was the result of a pipetting or other error that could be eliminated or reduced by increased automation of this assay. Finally, while not related to reproducibility of results, it should be noted that the metabolic competency of the cultures used in the present study is not well characterized and is expected to be limited in comparison to liver; this may impact results compared to in vivo neurotoxicity when metabolism is important in the activation or de-activation of a compound.
The screening approach taken here was aimed at identification of potential neurotoxicity hazard with the ultimate goal of prioritization for additional "second tier" screening and hazard characterization (e.g., potency determination, exposure assessment, relevancy of effective concentrations to human exposures, etc.). For efficiency and economics, neuroactive compounds were identified by screening a single, relatively high concentration (based on the maximally tolerated DMSO concentration for the assay) of each compound in triplicate. One potential pitfall with this approach is the possibility that this single concentration "misses" a compound effect because the concentration used is too low, or lies within a "no-effect" level on a biphasic concentration-response curve. As with any assay, inactive compounds can only be defined as such up to the highest concentration tested. With respect to biphasic responses, there are examples of such concentration-response curves for compound effects on MFR in cortical networks, including (but not limited to) glutamate, NMDA and glufosinate (Frega et al. 2012; Lantz et al. 2014) , nicotine (Hondebrink et al. 2016) and deltamethrin (Vassallo et al. 2017) . Thus, the possibility exists that there are some false negatives in the current assay.
With any screening assay, understanding the rate of false positives and false negative responses is important. As discussed above, since only eight compounds have been tested in neural networks in MEAs by multiple laboratories, evaluation of false response rates based on MEA studies is not possible at this time. When comparing neural network activity measurements with MEAs to known in vivo neuroactivity, previous studies have reported very low false positive rates McConnell et al. 2012; Valdivia et al. 2014; Vassallo et al. 2017) . By contrast, false negative rates (known neuroactive compounds that fail to alter activity in MEAs beyond the hit threshold) are ~20-25% in these same studies. Thus, based on these historical metrics, the present study is more likely to have underestimated the number of active compounds, and less likely to have incorrectly reported inactive compounds as active. Reasons for a false negative response may include concentration-selection issues (as discussed above), toxicokinetic issues (need for metabolism to an active compound), lack of sensitive receptors and/or cell populations. Whereas the small number of replicates (3 per compound) in the present study could increase the possibility for incorrect hit calls, this is mitigated by comparing pre-and post-treatment responses from the same well, and by conducting all three technical replicates within the same culture (see Malo et al. 2006) , which reduces biological (e.g., culture to culture) and experimental (e.g., day to day) variability.
Within the ToxCast phase II libraries, compounds are subdivided into groups or categories that serve to represent their primary use. Unsurprisingly, four of the five largest active compound use categories detected in the MEAs were pesticides, pharmaceuticals, fungicides, and herbicides. In many cases, compounds within these categories are known to target key neural processes, receptors and/or ion channels. This was evident in the categories of targets documented to be associated with these chemicals, which included both ion channels (both sodium and calcium) and neural receptors (e.g., GABA, ESR1, TACR1, and AChE), as well as those known to disrupt mitochondria, microtubule formation, and compounds inhibiting sterol biosynthesis (see Fig. 2 ). When assessing compound target sensitivity, the MEAs proved to be most sensitive in detecting compounds known to target ion channels (including 10/13 pyrethroid insecticides) and GABAergic input. In some cases, as with the previous study (Valdivia et al. 2014) , this MEA assay often detected active compounds that were not hits in other assays present in the ToxCast battery. For example, Silva et al. (2015) reported that two compounds with known in vivo neurotoxicity, methidathion and endosulfan, lacked activity in the ToxCast in vitro assay endpoints for acetylcholinesterase inhibition and interactions with the GABA A receptor, respectively, both of which are established molecular targets of these compounds (Silva et al. 2015) . Both of these compounds were identified as active in the mwMEA assay. The results with endosulfan are consistent with previous reports in MEAs (Valdivia et al. 2014; Dingemans et al. 2016 ).
An important caveat here is that the targets identified in the CPCat analysis may or may not be targeted within the neural networks on the MEAs. In this respect, previous analysis has indicated that heavy metals (identified in the current study as cytotoxic), surfactants and dithiocarbamate fungicides showed promiscuous activity across other ToxCast assays (Sipes et al. 2013) . Because network activity measured by MEAs can be altered by a variety of neural mechanisms, the precise mechanism of action is unknown. Thus, "off-target" or non-specific effects could underlie the changes in activity observed here. However, in the context of screening for potential hazard to the nervous system, it is advantageous to have an assay with broad sensitivity to a wide range of compounds. Subsequent follow-up or second tier studies can provide mechanistic information. In addition, the associations can be strengthened (but not proven) by approaches such as the chemotype enrichment analysis.
Similar to previous MEA studies (McConnell et al. 2012; Valdivia et al. 2014) , nicotine and neonicotinoid insecticides (with the exceptions of clothianidan and thiamethoxam) were not among identified hits. This may indicate an overall lack of sensitivity to nicotinic compounds or a false negative response (e.g., due to dose selection). Currently, this is difficult to assess, due to reports of varying effects of nicotine on MFR in cortical cultures on MEAs, including slight increases at 100 µM Hondebrink et al. 2016) , lack of statistically significant effects (≤500 µM; Mack et al. 2014) or significant inhibition (300-1000 µM; Hondebrink et al. 2016) . The α7 nicotinic ACh subunit is expressed on the neural somata and initial apical dendrite in primary cortical cultures; thus, the appropriate target is present. Effects of the nAChR-selective antagonist mecamylamine were limited to changes in burst duration and the percentage of spikes occurring in a burst (Hammond et al. 2013) . These parameters were not evaluated in the current or previous McConnell et al. 2012; Valdivia et al. 2014; Hondebrink et al. 2016) studies. Recent work has demonstrated that consideration of bursting characteristics as well as measures of network connectivity (e.g., correlated activity across electrodes) is most efficient for identification of compounds that alter neural network development (Brown et al. 2016; Frank et al. 2017, submitted) . Thus, a more comprehensive analysis that includes these metrics, may improve identification of compounds that alter network function following acute exposure.
Interestingly, a total of 17 compounds known to target estrogen receptor 1 (ESR1) altered neural network function. To date, effects of estrogen receptor agonists/antagonists on neural network function on MEAs have not been reported in the published literature. Thus, this represents a novel finding. These results are consistent with the well-established "rapid actions" (not mediated by nuclear activation) of androgens (Hill et al. 2015) and estrogens (Kow and Pfaff 2016) on a variety of ion channels relevant to neural network function (e.g., voltage-gated calcium and potassium channels and ionotropic GABA A , NMDA and AMPA receptors). Whereas most of these compounds are classified for use as pharmaceuticals (e.g., tamoxifen, 17α-estradiol, and diethylstilbestrol), compound use categories for these estrogenic compounds targeting ESR1, including plastics (bisphenol A and bisphenol AF), flavones (daidzein), dyes (4-nonylphenol), and chemical intermediates (e.g., 4-(1,1,3,3-tetramethylbutyl)phenol), were also represented. Consistent with the use category analysis, the structure-based chemotype enrichment analysis independently identified a defined subgroup of alkyl phenols highly enriched with mwMEA hits; the same chemotype was found to be enriched in the active sets of 16 ToxCast assays targeting nuclear receptors, ER and AR, establishing a significant association of the assay endpoints in this local chemistry domain.
The chemotype enrichment approach employed here offers a promising structure-based approach for mining and exploring ToxCast assay data. Such an analysis, can yield quantifiable statistics and transferable results, and can provide a starting point for further structure-activity exploration and mechanistic hypothesis generation within local domains of chemistry. The preliminary analysis presented here demonstrates an intuitive data mining strategy that can yield actionable structure-activity hypotheses for informing follow-up testing, as well as putative mechanistic associations across assay targets in local chemistry domains, associations that would likely have been obscured by a less chemically supervised, more global correlation analysis. For example, for the top 11 enriched chemotypes identified in 34% of the hits in the singlepoint screen, inactive chemicals containing those same chemotypes are candidates for false negatives and subsequent follow-up screening, whereas the same chemotypes might be used to preferentially nominate new chemicals for testing as candidate positives, or to prioritize a much larger set of chemicals for testing. It should be noted, however, that a major portion of the MEA hit space (66%) was not explored in this initial chemotype analysis. Considering additional chemical properties and features, or exploring combinations of chemotypes might be useful in accounting for a larger fraction of the hit space moving forward.
Conclusions
The present results demonstrate the ability of an MEAbased screen examining neural network activity to identify potentially neuroactive compounds from a set of over 1000 compounds. To date, this is the largest set of compounds screened for neuroactivity using this approach. An analysis approach that links the results in this assay to those in other ToxCast assays based on structural features of active compounds yielded actionable inferences that can be used to inform mechanistic hypotheses and guide follow-up studies. As such, data from this assay are helping to fill an important biological niche (neurotoxicity) where there are few cell-based, functional assays in the ToxCast battery of assays.
